Olivier Godeaux
About
Olivier Godeaux is a scholar working on Epidemiology, Infectious Diseases and Surgery.
According to data from OpenAlex, Olivier Godeaux has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Epidemiology, 4 papers in Infectious Diseases and 4 papers in Surgery. Recurrent topics in Olivier Godeaux's work include Herpesvirus Infections and Treatments (6 papers), Hepatitis B Virus Studies (5 papers) and Influenza Virus Research Studies (4 papers). Olivier Godeaux is often cited by papers focused on Herpesvirus Infections and Treatments (6 papers), Hepatitis B Virus Studies (5 papers) and Influenza Virus Research Studies (4 papers). Olivier Godeaux collaborates with scholars based in Belgium, United States and United Kingdom. Olivier Godeaux's co-authors include Thomas C. Heineman, Himal Lal, Janet E. McElhaney, Daisuke Watanabe, Shinn‐Jang Hwang, Lily Yin Weckx, Airi Põder, Timo Vesikari, Joan Puig‐Barberà and Myron J. Levin and has published in prestigious journals such as New England Journal of Medicine, The Journal of Infectious Diseases and Clinical Orthopaedics and Related Research.
In The Last Decade
Olivier Godeaux
19 papers receiving 1.3k citations
Hit Papers
Peers
Olivier Godeaux
Himal Lal Belgium
Airi Põder Estonia
Lidia Oostvogels Belgium
Janie Parrino United States
Jon E. Stek United States
J. W. Gnann United States
Atsuko Hata Japan
P. A. Brunell United States
Michael Remington United States
Greet J. Boland Netherlands
Citations per year, relative to Olivier Godeaux Olivier Godeaux (= 1×)
peers
Himal Lal
Countries citing papers authored by Olivier Godeaux
Since
Specialization
Citations
This map shows the geographic impact of Olivier Godeaux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Godeaux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Godeaux more than expected).
Fields of papers citing papers by Olivier Godeaux
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Olivier Godeaux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Godeaux. The network helps show where Olivier Godeaux may publish in the future.
Co-authorship network of co-authors of Olivier Godeaux
This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Godeaux. A scholar is included among the top collaborators of Olivier Godeaux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Godeaux. Olivier Godeaux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bihlet, Asger Reinstrup, Yves Henrotin, Peter Alexandersen, et al.. (2025). A single intra-articular injection of JTA-004, a combination of human plasma, hyaluronic acid, and clonidine, versus placebo in symptomatic knee osteoarthritis: A Phase 3 trial. Osteoarthritis and Cartilage. 34(2). 279–289.
2.
Richmond, Peter, Terry Nolan, Joshua Kim, et al.. (2024). Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents. Vaccine. 42(24). 126251–126251.
3.
Jayankura, Marc, Thierry Thomas, Lothar Seefried, et al.. (2023). Does Adjunction of Autologous Osteoblastic Cells Improve the Results of Core Decompression in Early-stage Femoral Head Osteonecrosis? A Double-blind, Randomized Trial. Clinical Orthopaedics and Related Research. 481(8). 1527–1540.
4.
Léon, Marc, et al.. (2021). Safety and efficacy of a single intra-articular injection of a novel enhanced protein solution (JTA-004) compared to hylan G-F 20 in symptomatic knee osteoarthritis: a randomized, double-blind, controlled phase II/III study. BMC Musculoskeletal Disorders. 22(1).
5.
Léon, Marc, et al.. (2020). Efficacy and safety of intra-articular injection of JTA-004, a novel supplemented protein solution, in osteoarthritic knee pain. Osteoarthritis and Cartilage. 28. S150–S150.
6.
Léon, Marc, et al.. (2020). FRI0400 EFFICACY AND SAFETY OF AN INTRA-ARTICULAR INJECTION OF JTA-004, A NOVEL ENHANCED PROTEIN SOLUTION, IN KNEE OSTEOARTHRITIS PAIN: A RANDOMISED, DOUBLE-BLIND CONTROLLED PHASE II/III STUDY. Annals of the Rheumatic Diseases. 79. 798–798.
7.
Williams, Kristi L., Arangassery Rosemary Bastian, Robert Feldman, et al.. (2020). Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years. The Journal of Infectious Diseases. 222(6). 979–988.
8.
Strezova, Ana, Olivier Godeaux, Naresh Aggarwal, et al.. (2017). A randomized lot-to-lot immunogenicity consistency study of the candidate zoster vaccine HZ/su. Vaccine. 35(48). 6700–6706.
9.
Schwarz, Tino F., Naresh Aggarwal, Isabelle Schenkenberger, et al.. (2017). Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older. The Journal of Infectious Diseases. 216(11). 1352–1361.
10.
Godeaux, Olivier, Martina Kovac, Daniel Shu, et al.. (2017). Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Human Vaccines & Immunotherapeutics. 13(5). 1051–1058.
11.
Schwarz, Tino F., Naresh Aggarwal, Isabelle Schenkenberger, et al.. (2016). Randomized, Phase III Clinical Trial to Assess the Immunogenicity and Safety of an Investigational Subunit Adjuvanted Herpes Zoster Vaccine Co-Administered With a Seasonal Quadrivalent-Inactivated Influenza Vaccine in Adults Aged 50 Years and Older. Open Forum Infectious Diseases. 3(suppl_1).
12.
Lal, Himal, Anthony L. Cunningham, Olivier Godeaux, et al.. (2015). Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. New England Journal of Medicine. 372(22). 2087–2096.
13.
Cunningham, Anthony L., Roman Chlíbek, Javier Díez‐Domingo, et al.. (2015). Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults by Region: Results of the Phase 3 ZOE-50 Trial. Open Forum Infectious Diseases. 2(suppl_1).
14.
Kosalaraksa, Pope, Robert Jeanfreau, Louise Frenette, et al.. (2014). AS03B-Adjuvanted H5N1 Influenza Vaccine in Children 6 Months Through 17 Years of Age: A Phase 2/3 Randomized, Placebo-Controlled, Observer-Blinded Trial. The Journal of Infectious Diseases. 211(5). 801–810.
15.
Godeaux, Olivier, Patricia Izurieta, Miguel G. Madariaga, et al.. (2014). Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years. Vaccine. 33(18). 2189–2195.
16.
Yang, William H., Marc Dionne, Naresh Aggarwal, et al.. (2013). Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial. Vaccine. 31(40). 4389–4397.
17.
Ferguson, Murdo, George Risi, Matthew Davis, et al.. (2012). Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant. The Journal of Infectious Diseases. 205(5). 733–744.
18.
Konno, Ryo, Kurt Dobbelaere, Olivier Godeaux, Shinobu Tamura, & Hiroyuki Yoshikawa. (2009). Immunogenicity, Reactogenicity, and Safety of Humar Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women. International Journal of Gynecological Cancer. 19(5). 905–911.
19.
Lehtinen, Matti, et al.. (2008). Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04 Adjuvanted Vaccine in Healthy Males Aged 10–18 Years. International Journal of Infectious Diseases. 12. e174–e174.
20.
Petäjä, Tiina, et al.. (2008). Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years. Journal of Adolescent Health. 44(1). 33–40.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Himal Lal Breakdown of academic impact, for papers by Airi Põder Breakdown of academic impact, for papers by Lidia Oostvogels Breakdown of academic impact, for papers by Janie Parrino Breakdown of academic impact, for papers by Jon E. Stek Breakdown of academic impact, for papers by J. W. Gnann Breakdown of academic impact, for papers by Atsuko Hata Breakdown of academic impact, for papers by P. A. Brunell Breakdown of academic impact, for papers by Michael Remington Breakdown of academic impact, for papers by Greet J. Boland